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DIFFERENTIATION OF UMBILICAL CORD BLOOD MESENCHYMAL 
STEM CELLS INTO ENDOTHELIAL CELLS 
SUMMARY 
Cardiovascular diseases are the most common causes of death in western countries. 
Autolog/allogeneic vessel transplantations or treatment with synthetics grafts are 
used for vessels with large diameter (>6mm) to improve life expectance of patients. 
For small-diameter (<6mm) vessel replacement, finding the correct sized sample 
from patient or donor becomes harder and synthetic models occluded too soon or 
they cannot resist to the blood flow pressure. The ultimate aim of this study is to 
produce endothelial cells as the first most important step of construction of a 
biological vessel graft. 
Stem cells have already been accepted as a promising source for tissue engineering in 
the near future. Umbilical cord blood became a reliable reservoir of mesenchymal 
stem cells (showing high plasticity) in the past few years.  
Mesenchymal cells from cord blood were isolated with the help of RosettaSep® 
and/or density gradient centrifugation to be cultured in MesenCult® Medium or 
Standard Medium containing Dulbecco’s modified Eagle’s medium-low glucose 
supplemented with 30% Fetal Bovine Serum and 0.1% 10–7 M dexamethasone with 
1% L-glutamine. Standard Medium was the best growth medium. However, the 
number of isolated mesenchymal stem cells from cord blood samples varied greatly 
in samples from person to person. On the other hand, microscopic and flow 
cytometric analyses proved that cord blood mesenchymal stem cells were same as 
the bone marrow mesechymal cells, showing fibroblastoid structure, adherent to 
plastic surface and expressing mesenchymal markers.  
In this research, differentiation of these cells into endothelial-like cells with the help 
of varying ratios of vascular endothelial growth factor have been tried.  
Mesenchymal cells treated with 50ng/ml and 55 ng/ml growth factor inside 
EndoCult® Medium or DMEM with 20%FBS maintained the best differentiation 
potential. Differentiated cells transformed from fibrolastoid structure into round 
endothelial morphology, expressing highest endothelial specific surface antigens.  
With this study, the differentiation potential of cord blood mesenchymal stem cells 
into endothelial cells to be used in construction of vessel graft for cardiovascular 
treatments was demonstrated. For future applications, a trustworhty and fast way to 
incrase the number of cord blood stem cells is needed, so that it can be cryopreserved 
in large numbers and can be used in time of request without any delay.   
  xvi
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KORDON KANI MEZENKİMAL HÜCRELERİNDEN DAMAR HÜCRE 
FARKLILAŞMASI  
ÖZET 
Kalp-damar hastalıkları, batı ülkelerindeki en yaygın ölüm sebebidir. Hastanın yaşam 
kalitesini arttırmak amacıyla, büyük çaptaki damarlar (>6mm), otolog/allojenik 
damar nakilleri ya da sentetik malzemelerin kullanımıyla tedavi edilmektedir. Küçük 
çaptaki damarların (<6mm) tedavisinde ise hasta ya da donörden uygun ölçütlerde 
damarın bulunması çok zorlaşmıştır ve sentetik modeller ya erken tıkanmakta ya da 
kan akış basıncına dayanamamaktadır. Bu çalışmanın esas amacı, oluşturulacak olan 
biyolojik damar modeli için gerekli endotel hücrelerin elde edilmesidir. 
Kök hücrelerinin, doku mühendisliğinde gelecek vaad eden bir kaynak olduğu kabul 
edilmiştir. Birkaç senedir kordon kanının, güvenilir bir mezenkimal kök hücre 
(yüksek farklılaşma kapasitesi gösteren) kaynağı olduğu ortaya çıkmıştır.  
RosettaSep® ve/veya yoğunluk farkı santrifüjü ile izole edilen kordon kanı 
mezenkimal hücreleri, MesenCult® Besiyeri ya da Standart Besiyeri (Dulbecco’s 
modified Eagle’s besiyeri-düşük glikoz, %30 Fetal Bovine Serum, %0.1 10–7 M 
dexamethasone ve %1 L-glutamine içeren) kullanılarak kültüre edilmiştir. Standart 
Besiyer en iyi büyümeyi sağlayan besi ortamıdır. Ancak, kordon kanından izole 
edilen mezenkimal kök hücrelerin sayısının örnekten örneğe büyük farklılık 
gösterdiği, insandan insana değiştiği gözlenmiştir. Bunun yanı sıra, mikroskobik ve 
akım sitometrisi analizleri ile, kordon kanından elde edilen mezenkimal kök 
hücrelerinin, kemik iliğinden elde edilen mezenkimaller gibi fibrilar yapıda, plastik 
yüzeye yapışan ve mezenkimal antijenlerinin anlatımını yapan özellikte olduğu 
ortaya konulmuştur.  
Bu çalışmada; farklı oranlardaki damar endotel büyüme hormonunun yardımı ile 
mezenkimal hücrelerinin endotel benzeri hücrelere farklılaşması denenmiştir. 
50ng/ml ve 55 ng/ml oranlarındaki büyüme hormonu ihtiva eden EndoCult® besiyeri 
ve %20 Fetal Bovine Serum içeren Dulbecco’s modified Eagle’s besiyeri en iyi 
mezenkimal hücre farklılaşmasını sağlamıştır. Farklılaşan hücreler, fibrilar yapıdan 
dairesel endotel morfolojisini verecek şekilde bir değişime uğramış; ve endotel 
hücrelere özgü yüzey antijenlerinin yüksek oranda anlatımını gerçekleştirmiştir. 
Bu çalışma ile, kordon kanı mezenkimal kök hücrelerinin, kalp-damar hastalıklarının 
tedavisinde kullanılmak üzere oluşturulacak yapay taşıyıcı için gerekli endotel 
hücrelere farklılaşma potansiyelleri gösterilmiştir. Gelecekteki çalışmalar için, 
kordon kanı kök hücrelerinin sayısını hızlı bir şekilde arttıracak güvenilir bir yolun 
bulunması gerekmektedir; böylece büyük oranlarda saklanması ve arzu edilen bir 
zamanda hiçbir gecikme olmaksızın kullanılması sağlanmış olunur.  
  xviii
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1.  INTRODUCTION 
The lack of organ and tissue donations causes a crisis and affects both transplantation 
field and reconstructive surgery. This problem provides an expansion of a new field 
called tissue engineering (Godara et al., 2008).  
Tissue engineering is defined as construction of living and functional components 
that can maintain, regenerate, or replace the malfunctioning tissues. The first report 
about tissue engineering was published in 1933 in which tumor cells that are covered 
in a polymer membrane for the protection were transplanted into a pig, but modern 
studies have started since 1980s with the development and clinical use of skin 
replacements (Polak and Bishop, 2006). “Tissue engineering” as a term was first 
coined in 1985 and in 1993 it was described as “an interdisciplinary field that applies 
the principles of engineering and the life sciences toward the development of 
biological substitutes that restore, maintain, or improve tissue function” (Niklason 
and Langer, 1997; Griffith and Naughton, 2002; Bajada et al., 2008; Godara et al., 
2008). Research continued to expand this field, however there are still some 
problems to be solved, like guaranteeing the product viability (Polak and Bishop, 
2006). 
The basic components of tissue engineering are cells, specialized microenvironments 
delivery systems and molecular signals (Godara et al., 2008). Over the past two 
decades, a quest for finding the best cell type for engineering studies resulted in 
recognition of stem cells which offered some important advantages. These 
advantages include, ability to self-renewal (giving rise to more stem cells) and ability 
to differentiate into any cell type under the appropriate circumstances (Polak and 
Bishop, 2006). 
The most important challenge of tissue engineering is optimizing the cell isolation 
and proliferation (rapid growth/production). On the other hand, differentiation of 
stem cells and steps of designing scaffolds and/or delivery systems needed to grow 
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three-dimensional tissues have also become important challenges. Harvesting cells 
from a patient is a popular technique, which will be expanded in culture conditions, 
and then they can be transferred onto a scaffold, which will work as a temporary 
environment until the cells produce their own extracellular matrix (ECM). A scaffold 
can also be used to help the growth of the tissue in which the scaffold will be 
destroyed as the new tissue forms (Polak and Bishop, 2006). Scaffolds have been 
designed from polymers, chitosan, collagen, gelatin, agarose, alginate etc. (Pountos 
et al., 2007). Even tough various cultivation methods are used to grow tissues, these 
techniques must also allow implantation of the grown tissue that contains sufficient 
number of cells with the correct phenotype. Newly grown tissue must be able to 
survive, restore and perform its unique biological function while integrating with the 
surrounding tissues (Polak and Bishop, 2006). 
One of the cell types that was used in tissue engineering is primary cells which are 
actually matured cells that are specific to a tissue type; for example primary human 
osteoblasts that are isolated from the femoral head. Primary cells are the most 
preferred ones because they exhibit immunological compatibility, however yields 
and proliferation rates are low. Moreover, isolation of primary cells from some 
phenotypes is impossible. These limitations have encouraged the scientists to find 
alternative cell sources, such as stem cells to eliminate some of the problems faced 
during the usage of primary cells (Polak and Bishop, 2006). 
1.1 Stem Cells 
Regenerative medicine is described as; “it aims at repair, replacement or regeneration 
of cells, tissue or organs to restore impaired function” by Daar and Greenwood, 
which means “it aids the body to form new functional tissue to replace lost or 
defective tissue”. Inside the human body, these regenerations and repairs are 
accomplished naturally by stem cells (Bajada et al., 2008). 
Stem cells are undifferentiated cells. They can proliferate and have the capacity for 
self-renewal and differentiation to various cell lineages (Polak and Bishop, 2006; 
Bajada et al., 2008). Another characteristic of stem cells is having the asymmetric 
division potential, which as a result generates two different daughter cells. One is 
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identical to the mother cell, and one is committed to a specific differentiation 
pathway. So that this intrinsic ability maintains constant stem cell number in a tissue 
while also giving rise to differentiated cells (Godara et al., 2008). 
First stem cell study was published by Becker et al. (1963) where bone marrow was 
transplanted to irradiated mice. As a result, nodule formations in spleens were 
observed with respect to the number of bone marrow cell transplanted, i.e., single 
bone marrow cell gave rise to a single nodule. 
Stem cells may be classified as embryonic stem cells (ESCs) and non-embryonic or 
adult stem cells (Bajada et al., 2008; D'Alessandro et al. 2010). There are different 
sources for the isolation of stem cells, they can be derived from embryos, fetuses, or 
adult tissues (Watt and Contreras, 2005), but the types of cell that they differentiate 
into show variations (Polak and Bishop, 2006).  
1.1.1 Embryonic stem cells 
ESCs were defined more than two decades ago, when they were isolated from the 
inner cell mass of the murine blastocyst during the development stage. ESCs are 
totipotent, which means they can construct the whole organism, that is they can 
differentiate into all cell lineages of ectodermal, mesodermal, endodermal origin and 
trophoblast (Wexler et al., 2003; Polak and Bishop, 2006). On the other hand, 
pluripotent (capable of differentiating into one of many cell types) ESCs can be 
isolated from inner cell mass of 5-6 day-old blastocysts (Bajada et al., 2008). In vitro 
ESCs can proliferate indefinitely in the undifferentiated state (Jiang et al., 2002) and 
with the help of appropriate signalling molecules they can differentiate into various 
somatic phenotypes (Zhao et al., 2006).  
Studies with medical applications of the stem cells began in 1998. Human ESCs 
show some differences compared to murine ESCs; they proliferate more slowly and 
mostly forming flat, but not spherical colonies. They also need to be grown on feeder 
layers in order to keep their self-renewal property (Polak and Bishop, 2006). 
For the culture conditions, most of the time, animal cells and proteins had been used 
and to be avoided from these, different ways such as addition of basic Fibroblast 
Growth Factor (bFGF), growth on matrigel or on human ESC fibroblasts etc. have 
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been tired.  Even though some of these methods have maintained the avoiation from 
the animal feeder cells, none of them is entirely animal free products, so the problem 
still remains (Polak and Bishop, 2006). 
In addition, one of the biggest concerns about ESCs is; the formation of tumor in 
vivo along with an unexpected differentiation (Goldberg et al., 2007; Passier et al., 
2008; D'Alessandro et al. 2010). 
For ethical problems of ESC (Jiang et al., 2002), different countries found different 
solutions to control its usage. To maintain ESCs, nuclear transfer technique, where 
nucleus from a donor cell is fertilized with enucleated oocyte to generate embryo, is 
also used. The first study about this nuclear transfer was published in 1952; yet the 
most popular one came in 1996 as known as Dolly the sheep (Bajada et al., 2008). At 
present, UK is the only country that gave permition for cloning of human ESC and it 
can only be used in therapeutic nuclear transfer, to create autologous cells for 
patients or to create diseased cells for in vitro pathogenetic or drug investigations. 
Reproductive cloning, on the other hand, is strictly forbidden (Polak and Bishop, 
2006). 
1.1.2 Fetal stem cells 
Another type of stem cell that is used for research is the fetal stem cells. Human fetal 
mesenchymal stem cells (MSCs) isolated from fetal blood were shown to survive 
about 20 to 40 passages in culture conditions and could differentiate into bone and 
cartilage, but also have the ability to produce oligodendrocytes and hematopoietic 
cells (Polak and Bishop, 2006). These cells can be found in the first- and second-
trimester fetal blood, bone marrow, liver and spleen (Chamberlain et al., 2007). Fetal 
MSCs are classified as multipotent stem cells (Godara et al., 2008). 
1.1.3 Adult stem cells 
Adult or somatic stem cells are undifferentiated cells that can be found inside a tissue 
or organ along with differentiated cells, such as those inside bone marrow, brain, 
liver, skin and the circulation system that can renew themselves (Polak and Bishop, 
2006; Jackson et al., 2007). The reason these stem cells exist is that they maintain 
and repair the tissues in which they are located (Caplan, 2007). This may be required 
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for a disease recovery, trauma or aging (Pittenger et al, 1999). These cells may be 
removed from a patient to be used in tissue construction, then the constructed piece 
could be reinserted to the same individual without the need for immunosuppression 
(Polak and Bishop, 2006). Recently tissue-specific stem cells’ differentiation into 
cells of other tissues have also been shown (Kim et al., 2004).   
However, some adult stem cells types inside a tissue/organ show low accessibility 
and frequency (e.g., ~1 stem cell per 100,000 bone marrow cells) (Polak and Bishop, 
2006). Restricted and reduced differentiation potential of these cells, in comparison 
to ESCs, is an another obstacle. This means that these cells can only differentiate into 
multiple lineages, and they are not pluripotent but multipotent with limited 
differentiation capacity. In addition, their low self-renewal ability and reduced 
proliferation capability (Jiang et al., 2002; Zhao et al., 2006; Bajada et al., 2008) 
limit their application possibilities for tissue engineering studies.   
Fat, placenta and spleen are all newly identified sources for stem cells. These sources 
may be as important as the other adult stem cell sources; since after 1 day of 
culturing, a single gram of human adipose tissue was reported to produce more than 
70,000 pluripotent stem cells (Polak and Bishop, 2006). 
Generally, some certain conditions are used to gain controlled differentiation of stem 
cells to produce the demanded phenotype. For such manipulations, addition of 
particular cytokines (regulatory proteins, take part in immune response), growth 
factors, amino acids, some proteins, active ions and co-culturing with a relevant 
cell/tissue type are needed. Moreover, a new approach to differentiate stem cells, i.e., 
incubating permeabilized stem cells with extracts of the target phenotype has become 
popular (Polak and Bishop, 2006).  
Besides from the use of natural adult stem cell sources, one of the newest and 
popular approaches consists of reprogramming of somatic stem cells with defined 
transcription factors to maintain embryonic stem cell-like state, generating so-called 
“Induced Pluripotent Stem (iPS) cells” (Lewitzky and Yamanaka, 2007; Stadtfeld, et 
al.2008). 
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1.1.3.1 Bone marrow stem cells 
One of the most preferred adult stem cells is bone marrow stem cells that can divide 
to give at least two classes of stem cells: hematopoietic stem cells (HSCs) and MSCs 
(Oswald et al., 2004; Rogers and Casper, 2004). 
Studies about bone marrow had started in late 1940s in animal models then carried 
out to human applications. The important thing about these studies was the survival 
of hematopoietic cells, which were isolated from the donor that was needed for 
treatment of leukemia and irradiation. Histocompability matching between donor and 
recipient is an important issue for successful HSC transplantation (Thomas, 1994). 
These stem cells have been used for many years to treat some hematological diseases 
(Rogers and Casper, 2004), hereditary disorders of metabolism, malignant solid 
tumors, congenital immunodeficiency and lower extremity ischemic disease (Hai-
Jiang et al., 2008). Bone marrow is the primary site for the production of these HSCs 
(Broxmeyer et al., 1989). HSC is a heterogeneous compartment including the cells 
with different proliferative and differentiative characteristics. Different activation 
and cell cycle states were observed within these cells. HSCs are multipotent that they 
are able to give rise to the whole hematopoietic system. Therefore, definition of HSC 
is the ability to reconstitute all hematopoietic lineage during the life-span of an 
individual (Watt and Contreras, 2005). During development stages, these cells are 
first encountered in the yolk sac, then seen in fetal liver and then in fetal bone 
marrow (Broxmeyer et al., 1989). Their differentiation potential is related with ECM 
molecules inside the bone marrow (Conget and Minguell, 1999) and it was reported 
that these stem cells are not limited to formation of blood cells but also have the 
potential to differentiate into liver, heart and skeletal muscle cells in animal studies 
(Wexler et al., 2003). They are also found in peripheral blood but not in large 
numbers (Broxmeyer et al., 1989). These type of stem cells are mostly classified 
according to their positivity for CD34 (Robinson et al., 2005) and CD133 cell surface 
markers (Watt and Contreras, 2005). 
About 130 years ago, a German pathologist Conheim had suggested that there are 
non-HSCs in the bone marrow (Chamberlain et al., 2007; Ohishi and Schipani, 
2010). These cells were initially isolated by Friedenstein et al. in 1960s (Kadivar et 
al., 2006; Bajada et al., 2008; Meyer et al., 2008), according to their adherence 
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property to the plastic cell culture plates (Alhadlaq and Mao, 2004). These cells, in 
turn, show multineage differentiation i.e., they are differentiated into bone and other 
mesenchymal lineages like adipocytes or chondrocytes under appropriate conditions 
(Lee et al., 2005; Pountos et al., 2007; Ohishi and Schipani, 2010). Later these kind 
of cells were named as MSCs by Caplan (1991), because of their differentiation 
potential into mesenchymal-type cells and it is also referred as bone marrow stromal 
cells because they arise from supporting structures of the bone marrow (Oswald et 
al.,2004; Chamberlain et al., 2007; Jazayeri et al., 2008). MSCs are mesodermal in 
origin (Low et al., 2008) that function as a natural system for tissue repairing 
(Pountos et al., 2007; Ohishi and Schipani, 2010); as precursor for bone, cartilage, 
muscle and lung (Conget and Minguell, 1999). MSCs are capable of migrating 
through circulation to the site of injury in response to signals under injury conditions 
and inflammation (Chamberlain et al., 2007; Pountos et al., 2007), yet the factors 
playing role in this behavior are unknown (Schmidt et al., 2006). MSCs in marrow 
represents ~1 in 10,000 nucleated cells isolated from mononuclear subset with the 
help of gradient centrifugation (Chamberlain et al., 2007) (Figure 1.1).  
 
Figure 1. 1 : Isolation scheme of mononuclear fraction (Pountos et al., 2007). 
The difference between HSCs and MSCs is that MSCs are fibroblastoid cells that can 
adhere on the plastic surface (Ohishi and Schipani, 2010), as a monolayer (Godara et 
al., 2008). Isolation of almost homogeneous MSCs can be accomplished by using 
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high density solutions with low viscosity and low osmotic pressure like Percoll or 
Ficoll (see also Figure 1.1). With the help of gradient differences, these solutions 
provide the environment to extract the mononuclear fraction which also includes 
HSCs (Pountos et al., 2007). Also, changing culture conditions to low oxygen 
tension may also help to get more homogenetic MSCs. Thus, it can be concluded that 
there are at least two types of stem cells in the bone marrow; HSCs and MSCs, which 
give rise to different cell types (Ohishi and Schipani, 2010) (Figure 1.2) 
 
Figure 1. 2 : Differentiation model for bone marrow stem cells. Adipocytes (Adp), 
chondrocytes (Chond), myoblasts (Myob), osteoblasts (Ob), and 
tendon/ligament fibroblasts (Tend/Lig) were shown to originate from 
MSCs in vitro, but whether there is only one single progenitor 
existence for each of them in vivo has yet to be answered. HSCs first 
differentiate into myeloid and lymphoid progenitors. Myeloid 
progenitors would differentiate into basophils (Baso), eosinophils 
(Eos), erythrocytes (Ery), monocytes (Mono), neutrophils (Neut), and 
platelets (Plt). Lymphoid progenitors differentiate into T (T) and B 
(B) lymphocytes and natural killer cells (NK). It was previously 
suggested that HSCs might differentiate into mesenchymal cells 
lineages too (Ohishi and Schipani, 2010). 
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Human MSCs (hMSCs) commonly express cell-surface antigens like CD13, CD28, 
CD33 (Wexler et al., 2003, Kim et al., 2004), CD71 (Pittenger et al., 1999), CD90 
(Thy1), CD106, CD29, CD166, CD44, CD73 (SH3), and CD105 (SH2) in vitro 
(Figure 1.3). But none of these antigens are unique/specific to MSC and they are 
mainly characterized by “their ability to differentiate into multiple mesenchymal 
lineages  including osteoctyes, chondrocytes, skeleton muscle cells under controlled 
in vitro conditions and their adherence to plastic surfaces” (Oswald et al., 2004; 
Wang et al., 2006). On the other hand, according to the International Society for 
Cellular Therapy (ISCT), bone marrow hMSCs must show positivity for CD73, 
CD90, and CD105 and no expression (<2%) of CD45, CD34, CD14, CD19, HLA-
DR (Ohishi and Schipani, 2010; Wexler et al., 2003; Conget and Minguell, 1999; 
Pittenger et al, 1999). These cells express intermediate levels of major 
histocompatibility complex (MHC) class I proteins but not MHC class II proteins. 
This phenotype is known as non-immunogenic; therefore, hMSC transplantation to 
allogenic host would not require immunosuppressive drug administration 
(Chamberlain et al., 2007; Liu et al., 2007c; Ohishi and Schipani, 2010). So far, bone 
marrow has been considered as the main source for MSCs but obtaining bone 
marrow is a discomforting procedure and the cell yield is very low (Secco et al., 
2008). 
 
Figure 1. 3 : Some positive cell-surface antigens and other (Stro-1, LNGFR, D7-
FIB) markers on MSC for phenotypic selection (Pountos et al., 
2007). 
hMSCs from bone marrow were used, following ex vivo expansion, to repair bone, 
cartilage defects and damaged kidney, to treat chronic skin wounds and ischemic 
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hearts in experimental models. Direct transfer of these cells into damaged brain of 
rats resulted in functional gain (Ohishi and Schipani, 2010). Their differentiation into 
osteogenic (Jaiswal et al, 1997; Conget and Minguell, 1999; Pittenger et al, 1999; 
Rogers and Casper, 2004), adipogenic (Pittenger et al, 1999; Wexler et al., 2003; 
Conget and Minguell, 1999) and chondrogenic cells (Yoo et al, 1998; Pittenger et al, 
1999; Wexler et al., 2003), as well as fat, tendon, muscle, marrow stroma (Pittenger 
et al, 1999; Conget and Minguell, 1999; Rogers and Casper, 2004; Wang et al., 
2006), neural cells (Sanchez-Ramos et al, 2000; Rogers and Casper, 2004; Low et 
al., 2008), endothelial-like cells (Oswald et al., 2004; Liu et al., 2007b; Jazayeri et 
al., 2008), hepatocytes and cardiomyocytes (Kang et al. 2006) were shown in vivo or 
in vitro.  
Although the ways to initiate proliferation and differentiation of hMSCs in vivo are 
not well understood, for an efficient in vitro differentiation, influence of basal 
nutrients, cell density, spatial organization, mechanical forces, growth factors and 
cytokines is critical (Pittenger et al, 1999). 
Recently it has been suggested that pluripotent stem cells may also exist in bone 
marrow and can give rise to tissues that are derived from all germ layers (ectoderm, 
mesoderm and endoderm) (Ohishi and Schipani, 2010).  
Bone marrow is a useful source for stem cells. However, harvesting these cells is an 
invasive procedure and the amount and quality of isolated cells may be affected by 
age (Bajada et al., 2008). Telomere lengths of the chromosomes in these bone-
derived cells were found to be shorter than that in the fetal-derived ones (Hai-Jiang et 
al., 2008). 
Except for the bone marrow, MSCs or MSC-like cells are also found in fat, placenta, 
amniotic fluid, dental pulp, tendons, synovial (joint fluid) membrane, skeletal 
muscle, peripheral blood and umbilical cord blood (Wexler et al., 2003; Bajada et al., 
2008; Ohishi and Schipani, 2010) (Figure 1.4). In order to prove useful, these new 
cell sources must have the similar potential of ESCs, demonstrate a strong capacity 
to proliferate and should easily be obtained in large quantities (Rogers and Casper, 
2004). 
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Figure 1. 4 : Different sources for MSCs and their differentiation potential in vitro 
(Bajada et al., 2008). 
1.2 Umbilical Cord Blood 
The interest about umbilical cord started in 1974 and the initial study were carried 
out in year 1982 (D'Alessandro et al. 2010). In past 10 years, cord blood 
transplantation applications has found its place in modern clinical practice (Lee et al., 
2004) for various blood diseases (Lu et al., 2005). First example of transplantation 
was performed in 1988 to treat an anemia patient, which suggested that cord blood 
itself contains sufficient amount of HSCs to recover the host lymphohematopoietic 
compartment (Gluckman, 2000; D'Alessandro et al. 2010). In umbilical cord blood 
(UCB), there are several types of stem cells including; 1- HSCs, expressing CD34, 
CD31, CD59, Sca-1, Thy 1, Oct-4, Nanog, SOX2, FGF-4, 2- MSCs [showing 
positivity for CD105, CD73, CD90, CD166, CD29, CD44, HLA-I and negativity for 
HLA-II, CD80, CD31, CD34 and CD45 etc. (Robinson et al., 2005; Lu et al., 2005)], 
3-side population cells which can give rise to myogenic and hematogenic cells and 4-
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endothelial progenitor cells (having less potential to differentiate than stem cells) 
expressing CD34, GATA2, Flk-1 (Rizvanov et al., 2008), improving the 
revascularization of organs or tissues after ischemic diseases, 5-rare pluripotent stem 
cells (Watt and Contreras, 2005).  
Nevertheless, the cord blood is mainly a rich source for HSCs (Lee et al., 2005; Liu 
et al., 2007a; Goldberg et al., 2007; Secco et al., 2008). Even though number of 
HSCs derived from a single cord blood is very low (Robinson et al., 2005; Hai-Jiang 
et al., 2008), it has been used so far for the treatment of acute leukemia, bone marrow 
hypoplasy, hemoglobinopaties and for some immunodeficiency (Cuneo et al., 2004).  
Due to the ease of collection, when compared to bone marrow stem cells, the 
importance of both UCB and peripheral blood were confirmed (Rogers and Casper, 
2004). UCB eliminates invasive surgery procedures of bone marrow transplantations 
(D'Alessandro et al. 2010). Besides, from its ease of collection, umbilical cord stem 
cells can be banked more easily, showing low incidence of rejection of the transplant 
with high cellular proliferation and plasticity (differentiation ability) and low 
possibilities of viral or bacterial transmission. Moreover, it is not an expensive 
procedure and without any ethical or legal concerns (Cuneo et al., 2004; Barker and 
Wagner, 2003; Ju et al., 2006; Goldberg et al., 2007), it can be collected without 
harming mother or the newborn (Bajada et al., 2008; Stanevsky et al., 2009). So far, 
UCB has already been proven as a useful source for HSCs (Broxmeyer et al., 1989; 
Nayar et al., 2002; Lee et al., 2004; Lu et al., 2005; Robinson et al., 2005; Stanevsky 
et al., 2009) as an alternate source to bone marrow and peripheral blood cells for 
HSC transplantation (Gilmore et al., 2000; Hong et al., 2005). These cells express 
CD34 and CD133 surface antigens (Goldberg et al., 2007). Umbilical cord blood 
hematopoietic stem cells (UCB-HSC) were first used as an alternative for bone 
marrow transplantation in 1988 and by 2004 the patient still remains alive and 
healthy (Rogers and Casper, 2004; Watt and Contreras, 2005). In addition, their 
differentiation potential to muscle, neuron, bone cells (D'Alessandro et al. 2010) and 
matured endothelial cells were demonstrated by different laboratories (Goldberg et 
al., 2007) (Figure 1.5). These stem cells are not fully differentiated, that is, they can 
adapt more easily, showing high compatibility (Rogers and Casper, 2004). However, 
the amount of stem cells isolated form umbilical cord is less (Cuneo et al., 2004; 
Barker and Wagner, 2003), with 1-3% from bone marrow versus 0,5-1% from UCB 
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(D'Alessandro et al. 2010). Another disadvantage of UCB is that a single donation 
can be available from a specific donor (Watt and Contreras, 2005).  
 
Figure 1. 5 : HSCs (shown here as SC) plasticity which can also be used in gene 
therapy and therapeutic cloning (Cuneo et al., 2004). 
The presence of MSCs in UCB was proven by different groups without the 
expression of CD14, CD34, CD45 (Lu et al., 2005). Their differentiation potential 
under the appropriate conditions was also shown (Rogers and Casper, 2004). These 
cells are multipotent (Goldberg et al., 2007); yet sometimes referred as pluripotent 
(Lu et al., 2005; Ladage et al., 2007). They are single nucleated, rapidly growing and 
have fibroblast-like morphology (Ju et al., 2006) (Figure 1.6). 
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Figure 1. 6 : Phase-contrast view of umbilical cord blood mesenchymal stem cells 
(UCB-MSCs) that are adhering to plastic surface and with fibroblast-
like appearance similar to that observed in bone marrow derived-
MSCs (Lu et al., 2005).  
Both UCB and bone marrow-derived MSCs share common cellular properties such 
as multilineage differentiation potential and gene expression profile (Hong et al., 
2005). From MSC to bone, cartilage, adipose and neural tissue differentiations were 
demonstrated (Goldberg et al., 2007; Low et al., 2008). Similarly, differentiation to 
hepatocyte-like cells (Hong et al., 2005), neuroglial-like, osteoblasts, chondrocytes 
and adipoctyes were also demonstrated (Lee et al., 2004). Besides from 
differentiation to osteogenic and adipogenic cells, Lu et al. (2005), showed that the 
long-term transgene expression in UCB-derived MSCs could be maintained by 
lentiviral vectors. The main difference between bone marrow MSCs and UCB-MSCs 
is that the number and the yield of the umbilical derived ones are lower (Rogers and 
Casper, 2004). On the other hand, presence of MSCs in endothelium and 
subendothelium layers of umbilical cord vein was also shown and differentiation into 
cardiomyocytes was observed (Kadivar et al., 2006). Nevertheless, MSCs were also 
observed in the cord itself and placenta, which provides a good opportunity of 
storage (Secco et al., 2008). 
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1.3 Purpose of the Study 
Blood vessels function as a carrier from heart to organs and tissues and to heart 
again. Vessels divide into two classes as arteries and veins; which vary in size, 
mechanical property and structure etc. depending on the volume of blood to be 
carried and flow rate. The native arteries are composed of three distinct layers 
(Ratcliffe, 2000): 
1. The innermost layer called the intima which is composed of a single layer of 
endothelial cells to form endothelium for preventing thrombus formation 
2. The middle layer or media is composed of multiple layers of smooth muscle 
cells (SMCs) within a surrounding ECM composed of collagen types I and 
III, elastin fiber and various proteoglycans 
3. The outermost layer is the adventitia that is composed of fibroblasts and 
randomly arranged collagen 
Increased prevalence of cardiovascular disease is the leading cause of death 
worldwide (Brewster et al., 2007), especially in western societies (Liu et al., 2007c, 
Zhang et al., 2007). According to statistics of year 2000, 39.4% (2.4 million people) 
of deaths was caused by cardiovascular diseases in United States (Boland et al., 
2004). There are still 71 million individuals with cardiovascular disease in USA 
(Goldberg et al., 2007). In Turkey, approximately 35% of death is caused by 
cardiovascular diseases (Akgün et al., 2007).  Most common cardiovascular problem 
is atherosclerosis (Sales et al., 2005), in the form of coronary artery and peripheral 
vascular disease (Miller et al., 2004), in which arterial walls thicken and decrease the 
volume of vessel lumen (Boland et al., 2004). 
The current treatments for some cardiovascular diseases include transplantations of 
arterial and venous vessels as biological grafts. Usually, autologous saphenous veins 
and internal mammary arteries are used to bypass occluded arteries (Mitchell and 
Niklason, 2003; Sales et al., 2005), but most of the time to find an available suitable 
tissue becomes impossible (Nerem, 2000, Nugent and Edelman, 2003) because of a 
previous surgery or vessel disease (Zhang et al., 2007). Moreover, this kind of 
processes may require multiple surgeries as well (Gao et al., 2008). Tissue or organ 
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donation is another solution; however, due to the donor shortages for the transplant 
surgery (Langer and Vacanti, 1993), most patients do not survive the long waiting 
periods for a transplant. Therefore, transplantion alone is not a viable solution.  
Some synthetic materials initially developed to overcome the problems about 
biological grafts. In 1952, surgical treatment of atherosclerosis began by replacing 
the diseased vessel with a synthetic graft (Hoerstrup et al., 2001).  This led to the 
widespread clinical usage of expanded polytetrafluoroethylene (e-PTFE) and woven 
or knitted polyethylene terephthalate (PET) fibers (Dacron) especially in large 
diameter vessels (>6mm) (Boland et al., 2004). However, biocompatibility issues 
with these materials were soon realized (Gao et al., 2008). 
For the therapy of small-diameter vessels (<6mm), autologous tissues were used, yet, 
because of the difficulties in finding adequate amounts of tissue, artificial grafts were 
tried (Niklason et al., 1999). Unfortunately, these grafts have failed to function 
successfully (Zhang et al., 2007; Ratcliffe, 2000) because of their unability to recover 
the damage (Nugent and Edelman, 2003), early thrombosis formation (Mitchell and 
Niklason, 2003; Brewster et al., 2007; Goa et al., 2008), chronic inflammation, 
microbial infection (Hoerstrup et al., 2001).  
Although some new drugs and devices improved the quality of life for patients, they 
did not significantly decrease mortality rates (Nugent and Edelman, 2003). 
The increasing prevalence of cardiovascular diseases (Zhao et al., 2006) and lack of 
eligible donors for transplants emphasized the importance of cell transplantation and 
tissue engineering including stem cell transplantations (Goldberg et al., 2007), to 
build blood vessels, especially small-diameter blood vessels, to supply the increasing 
need (Vaz et al., 2005).  
MSCs are multipotent (D’Alessandro et al., 2010) and they can differentiate into 
multiple lineages (Kim et al., 2004), therefore their usage in tissue engineering 
increased (Godara et al., 2008). In addition, MSCs are non-immunogenic 
(Chamberlain et al., 2007) that can be used easily without any immunosuppressive 
drugs. Bone marrow MSCs were used so far to produce endothelial-like cells 
(Oswald et al. 2004); however, there are several issues with their use, as explained 
above. Besides, bone marrow MSCs number and differentiation capacity decrease 
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with age (Kang et al., 2006), creating another problem for its therapeutic potential 
use (Bieback et al., 2004). These facts led scientists to search for a new source for 
MSCs and one of the reliable and alternative source found out to be the UCB. 
The aim of this study is to isolate UCB-derived MSCs and differentiate them into 
endothelial cells in vitro which have not been done so far. Results of this study could 
be an important step towards contribution to vessel engineering to develop patient 
specific tissue for the treatment of cardiovascular diseases.   
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2.  MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Native vessel sample 
Vessel samples were kindly provided by the Department of Urology in the Istanbul 
University Cerrahpaşa School of Medicine. Samples were kept in Phosphate-
Buffered Saline (PBS) solution (Invitrogen, USA) at 4oC until use. 
2.1.2 UCB samples  
Samples were donated by 15 women who gave birth in hospitals of several local 
universities and obtained following normal or caeserian term deliveries, in 
accordance with ethical standards of the local ethical committee. 
2.1.3 Solutions and culture media 
2.1.3.1 Isolation solutions for MSCs  
RosetteSep® Human Mesenchymal Stem Cell Enrichment Cocktail (Stem Cell 
Technologies, USA) contains combinations of mouse and rat monoclonal antibodies 
that are bound in bispecific tetrameric antibody complexes which were raised against 
cell surface antigens on HSCs (CD3, CD14, CD19, CD38, CD66b) and glycophrin A 
on red blood cells. It enriches MSCs by crosslinking the undesired cells. Hanks’ 
Balanced Salt Solution Modified (Invitrogen, USA) (Table 2.1) was used to diluate 
the blood and Ficoll-Paque (TM) Plus (Stem Cell Technologies, USA) or Biocoll 
separating solution (Biochrom AG, Germany) was used for density gradient 
centrifugation to isolate mononuclear cells and MSCs, from the total cord blood. 
PBS was also used in isolation process to wash out cells during centrifuge steps. 
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Table 2. 1 : Components of Hanks’ Balanced Salt Solution 
INORGANIC SALTS g/L 
Calcium Chloride·2H20 0,185 
Magnesium Sulfate (anhydrous) 0,09767 
Potassium Chloride 0,4 
Potassium Phosphate Monobasic 
(anhydrous) 
0,06 
Sodium Chloride 8,0 
Sodium Phosphate Dibasic (anhydrous) 0,04788 
OTHERS  
D-Glucose 1,0 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
2,38 
Sodium·Bicarbonate 0,35 
2.1.3.2 Culture medium for MSCs 
MesenCult® MSC Basal Medium (Human) with Mesenchymal Stem Cell 
Stimulatory Supplements (Stem Cell Technology; USA) were used together to form 
the appropriate medium to optimize growth conditions of MSCs and expansion of 
them. Basal Medium is based on McCoy’s Medium (Bieback et al., 2004) (Table 2.2) 
and 10% Fetal Calf Serum. 
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Table 2. 2 : Components of McCoy’s Medium, adapted from Url-1. 
 
As a second medium for MSCs, Dulbecco’s modified Eagle’s medium (DMEM)-low 
glucose (Biochrom AG, Germany) supplemented with 30% Fetal Bovine Serum 
(FBS) (Gibco, USA) and 10–7 M dexamethasone (Invitrogen, USA) in a ratio of  
0.1% (Değiştirici et al., 2008) with 1% L-glutamine (Gibco, USA) was used and 
named as Standard Medium.  
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2.1.3.3 Culture medium for endothelial cells 
EndoCult® Liquid Medium Kit (Stem Cell Technology, USA) containing EndoCult® 
Basal Medium and EndoCult® Supplement is needed for the growth of endothelial 
cells. 
DMEM-low glucose (Biochrom AG, Germany) supplemented with 10%-20% FBS 
(Gibco, USA) and 1% L-glutamine (Gibco, USA) was also used. 
2.1.4 Antibodies 
2.1.4.1 MSC antibodies 
To characterize the phenotype of some cell-surface antibodies like anti-CD133-PE 
(phycoerythrin-conjugated), anti-CD44-FITC (fluorescein isothiocyanate-
conjugated) (eBioscience, USA), anti-CD73-PE (Biolegend, USA), anti-CD90/Thy-
1-FITC, anti-CD105/SH2-PE, anti-CD34-PE, anti-CD45-FITC (Beckman Coulter, 
USA) were used.  
2.1.4.2 Endothelial antibodies  
To verify MSCs differentiation into endothelial cells, some antibodies to inspect the 
phenotype of developed cells were used, such as anti-VCAM-1/CD106-PE 
(eBioscience, USA), VE-Cadherin/CD144, and anti-CD309/KDR/VEGFR2 
(vascular endothelial growth factor receptor 2) (Beckman Coulter, USA). 
2.1.5 Dyes 
Trypan Blue (Invitrogen, USA) was used for counting viable cells. 
2.1.6 Chemicals 
Trypsin-EDTA (Gibco, USA) was used in subcultivation process to detach cells from 
surface. 
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2.1.7 Growth factors 
Vascular endothelial growth factor (VEGF) from mouse and human (Millipore, 
USA) helped differentiation of UCB-derived MSCs into endothelial cells. 10µg 
lyophilized VEGF was diluted with 4 ml of sterilized water and aliquoted as 150µl so 
each tube of 150µl contained 375ng VEGF to be stored. 
2.1.8 Laboratory equipments 
Flow cytometry    Beckman Coulter Epics XL                       
Pipettes     Pipetteman P10 (Eppendorf)               
Microscope     Olympus IX71                                  
Incubator     Thermo electron corporation Hera cell 240 
Laminar air flow cabin   Hera safe KS12                                     
Centrifuge     Beckman Coulter                                          
Water distillation system   Millipore                                                        
Deep freezer     Arçelik 2021 D                                    
Refrigerator     Arçelik 1061 M 
2.2 Methods 
2.2.1 Collection of UCB samples 
UCB units were collected mostly from full-term deliveries with the consent of 
mothers. Sample bags containing 28ml of citrate phosphate dextrose (CPD) 
anticoagulant were used.  
Due to the decreasing activity of the stem cells over prolonged period (Kang et al., 
2006), collected UCB samples were processed within 24 hrs.  
2.2.2 Isolation of MSCs 
A wide number of protocols exist for MSC isolation (Pountos et al., 2007). In the 
current study, MSCs were isolated via density gradient centrifugation. Four ml of 
blood samples were taken into 15ml Falcon tubes, followed by addition of 50 µL 
RosettaSep® Human Mesenchymal Stem Cell Enrichment Cocktail per mL of blood 
 24
sample (200µL in this case). Tubes were then incubated for 20 min at room 
temperature to eliminate undesired cell types, such as red blood cells (Figure 2.1).   
 
Figure 2. 1 : Unwanted cells are cross-linked with red blood cells to form tetrameric 
antibody complexes, adapted from Url-2. 
Hanks’ Balanced Salt Solution was then added to each tube in a ratio of 1:1 and 
gently mixed. After, this mixture in each tube was layered onto 6ml of Ficoll-Paque 
(TM) Plus solutions (in different Falcon tubes of 15ml) slowly to minimize the 
mixing of Ficoll and blood sample (Alhadlaq and Mao, 2004; Kang et al., 2006; 
Ernsting et al., 2007). The tubes were then centrifuged for 25min at 1800 rpm at 
room temperature (Figure 2.2), to separate the mononuclear cells containing MSCs 
via density gradient centrifugation (Lee et al., 2005; Hirata et al., 2005). Cell 
viability was determined by trypan blue dye exclusion method (Fan et al., 2009). 
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Figure 2. 2 : Scheme of isolation for desired cells (MSCs), adapted from Url-2. 
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Following the centrifugation, plasma fraction was discarded and MSCs which took a 
shape of a colloidal ring inside the tube were replaced slowly to new 15ml tubes. The 
cells were washed with PBS or Hank’s Balanced Salt Solution (HBSS) in a ratio of 
1:1 and centrifuged at 1200 rpm for 10 min at room temperature. Supernatant was 
discarded, obtaining a MSC pellet. 
2.2.3 Culture and expansion conditions of MSCs 
Isolated MSCs (the pellet) were resuspended in 2ml of expansion media which was 
composed of 1/10 dilution of Mesenchymal Stem Cell Stimulatory Supplements and 
MesenCult® MSC Basal Medium (Human) or in Standard Medium. Roughly 2x106 
cells (counted following trypan blue staining) were seeded in vented T-25cm2 flasks 
having 5-10ml of media. Trypan blue only stains dead cells. 
Cells were cultivated in a carbondioxide incubator (Thermo Scientific Heracell 240) 
(5% CO2 at 370 C). The first medium refreshment was within 3 days for MesenCult® 
medium and daily for Standard Medium to remove non-adherent cells and then every 
2 or 3 days for MesenCult®, and weekly for Standard Medium. Medium refreshment 
was continued until 70% confluency was obtained, after approximately 14 days of 
cultivation.  
MSCs were recovered using a cell scraper and studied under the light microscope. 
Adherent cells with fibroblast-like appearance were taken into 15ml tube and 
centrifugated at 1500rpm for 5min. Supernatants were discarded and cell were 
resuspended with medium and reseeded at 2x106 cells per flasks and named as 
passage 1 (P1) cells. 
On the other hand, for the subculturing of MSCs that grew in Standard Medium, 
trypsin-EDTA was used. After reaching 70% confluency, medium was moved and 
the cells were washed with PBS. 2ml of trypsin-EDTA was then added and the flask 
was kept inside the incubator for 5min. 2ml of fresh Standard Medium was added to 
collect the detached cells for centrifugation at 1500rpm for 5 min. Supernatant was 
discarded again and cells were resuspended with Standard Medium and reseeded at 
2x106 cells per flasks and named as passage 1 (P1) cells. 
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2.2.4 Characterizaton of MSCs by flow cytometry 
Even though there are no specific cell surface marker for MSCs, literature survey 
revealed that different laboratories have chosen wide range of antibodies for 
characterization. Anti-CD133 (Oswald et al., 2004; Kern et al., 2006), anti-
CD73/SH3 (Bieback et al., 2004; Oswald et al., 2004; Lee et al., 2005;  Kadivar et 
al., 2006; Chamberlain et al., 2007), anti-CD90/Thy-1 (Bieback et al., 2004; Oswald 
et al., 2004; Kern et al., 2006; Chamberlain et al., 2007), anti-CD105/SH2 (Bieback 
et al., 2004; Oswald et al., 2004; Chamberlain et al., 2007; Jazayeri et al., 2008) anti-
CD34, anti-CD44, anti-CD45 (Pountos et al., 2007) were used. CD45, CD34 and 
CD133 are typical hematopoietic linage markers (Gilmore et al., 2000; Kim et al., 
2004) used as control markers in this study. These markers were chosen to identify 
the isolated cells, whether they were MSCs or not.  
Approximately 107 cells from culture samples were taken and resuspended . 100µl of 
sample was incubated with 20µl of isotypic solution for control tube and with 20µl 
of antibody for test tubes for 20 min at room temperature in the dark to be used in 
flow cytometry. Dual labeling was also conducted, by incubating with two 
antibodies. 
2.2.5 Endothelial differentiation of UCB-MSCs 
Freshly isolated MSCs were seeded in six-well cell culture plates and cultured in 
endothelial differentiation medium containing 2 ml of EndoCult® Supplement to 
every 8ml of EndoCult® Basal Medium (1/5 dilution) with 40, 45, 50, 55 or 60 
ng/mL VEGF. These cells were incubated at 370C for 13 days. Medium was replaced 
every 2 days.  
For endothelial differentiation cells from P(5) that grew inside the Standard Medium 
were seeded as three well cluster in DMEM/FBS (20%) and refreshed every 2 days 
for 7 days. Cells that received only DMEM and 20% FBS was the control group, and 
the two well contained DMEM+20%FBS with 50ng/ml and 55ng/ml VEGF 
respectively (experiment group). The medium was replaced every 2 days. 
MSCs from P(0) that also grew in Standard Medium were cultured in DMEM-low 
glucose+10% FBS+1% L-Glutamine with 50ng/ml human VEGF. Addition of VEGF 
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into cultures was done every 2 days during the first 10 days, and increased to 
everyday addition afterwards. 
2.2.6 Characterizaton of the differentiated endothelial cells  
To verify the differentiation, expression of specific endothelial markers such as 
VCAM-1, KDR/VEGFR2 (Oswald et al., 2004; Jazayeri et al., 2008) and VE-
Cadherin/CD144 (Oswald et al., 2004; Kern et al., 2006; Liu et al., 2007b) were 
monitored by flow cytometry. 20µl of the antibodies listed above was added to 
~2x105 cells (in 4ml round-bottom tubes) for these studies.  
2.2.7 Isolation of endothelial cells from native vessel 
As previously described by Marelli-Berg et al. (2000), samples were treated with 
collagenase enzyme (0,5mg/ml) for 1 h at 37oC. Undigested blocks were removed by 
using a cell strainer and isolated endothelial cells were washed with PBS for 10 min 
at 1200 rpm to be cultivated in DMEM-low glucose supplemented with 10-30% FBS 
and 1% L-glutamine. 
Furthermore, undigested blocks were treated with collagenase enzyme (0,5mg/ml) 
overnight to optimize the best isolation condition for endothelial cells. 
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3.  RESULTS AND DISCUSSION 
Tremendous improvements both in cell biology and cell culture have led to the birth 
of tissue engineering (L’Heureux et al., 1998) as a part of regenerative medicine 
(Atala, 2007).  
There are three main strategies for tissue engineering (Kuo and Tuan, 2003; Griffith 
and Naughton, 2002):  
1. Using engineered matrices alone to maintain the migration of cell onto 
scaffold to populate there,  
2. Injection autologous, allogeneic, or xenogeneic cells alone,  
3. Placing of cells placed on or within constructed biodegradable matrices which 
functions as synthetic temporary extracellular matrix until the cell form their 
own matrix.  
For construction of a vascular graft, the engineered vessel should carry some 
properties like being lack of thrombogenicity, resistant to infections and have the 
ability to heal, remodel, contract, and secrete normal blood vessel products (Kakisis 
et al., 2005). Weinberg and Bell (1986) were the first to report the in vitro 
construction of a biological vessel to become pioneers in this field (Mironov et al., 
2008). They used collagen gel with bovine endothelial cell, smooth muscle and 
fibroblast, but it failed to show enough mechanical strength. 
Isolating autologous cells via biopsy from patients will not maintain enough healthy 
cells for expansion and for construction of vascular graft. Besides, aging is also a 
limitation factor, which affects the doubling capacity of autologous vessel cells 
(Brewster et al., 2007; Liu et al., 2007c). Therefore, an autologous source with high 
proliferative capacity to enable isolation and expansion of cells to large numbers is 
necessary. 
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Stem cells have the potential to significantly change the future of tissue engineering 
(Bianco and Robey, 2001), so expanding patient’s own stem cell to repair or 
regenerate the required human tissue can be used as a therapeutic approach (Goltry et 
al., 2007). 
Therapeutic trials have demonstrated that MSCs are important cell population with 
supporting and differentiating characteristics to regenerate injured tissues. Most 
widespread applications of MSCs include bone defect repair, adipose tissue 
development, cartilage repair (Godara et al., 2008). Some trials on myocardial 
infarction treatment (Kim et al., 2004; Kern et al., 2006; Ladage et al., 2007), spinal 
cord (Pountos et al.,2007) and bladder regeneration (Bajada et al., 2008) were also 
tried. 
Bone marrow is the first and most common source for MSCs. Marrow MSCs are also 
named as “BMSC (bone marrow stromal cells), BMSSC (bone marrow stromal stem 
cells), CFU-F (colony forming unit-fibroblastic), SPC (stromal precursor cells), 
MAPC (multipotent adult progenitor cells), MPC (mesodermal progenitor cells), and 
RS (recycling stem cells)” (Godara et al., 2008). Marrow MSCs have the potential to 
differentiate down a range of lineages of mesenchymal tissues and also have the 
ability to provide the microenvironment essential for the maintenance, proliferation 
and differentiation of hematopoietic stem cells (Wexler et al., 2003; Kim et al., 2004; 
Jackson et al., 2007; Fan et al., 2009).  
For cardiovascular diseased patient, autologous patient-derived marrow stem cells 
maintain the avoidance of potential allogeneic immune reactivity, but large volume 
collection at an active time of cardiovascular disease may result in inadequate 
response due to age-related number and activity reduction. These reductions may 
cause longer extension period in culture, limited migration potential and increased 
senescence in vitro when it is compared to non-patient ones (Goldberg et al., 2007). 
These potential unfortunate problems led a search for an alternative, reliable source 
for cell transplantation and therapy like fat, skin, peripheral blood, some fetal tissues 
(blood, marrow, lung) (Jackson et al., 2007), muscle (Meyer et al., 2008) and 
umbilical cord blood. 
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Some groups had reported isolating stem cells from endothelial layer (Kadivar et al., 
2006), subendothelial layer of cord vein (Low et al., 2008) or Wharton’s jelly (Secco 
et al., 2008) which is a mucoid connective tissue that surrounds two arteries and vein 
of the cord (Meyer et al., 2008). However, because of the ease of collection and 
transportation, cord blood was preferred in this study. 
One of the biggest obstacles about UCB is the amount of stem cells that are obtained. 
UCB includes lower number of MSCs. When it is compared with bone marrow, 
which contains 2–5 MSCs every 106 MNCs, UCB only has 0.05–2.8 MSCs in every 
106 MNCs (Fan et al., 2009). 
For a successfully repairment of an injury or tissue, critical number of stem cells is 
required. Small number of cells needs longer time to adjust; to overcome the 
problem, which may result in death of the patient. On the other hand larger cell 
number will contribute to recovery more quickly. In addition, since the amount of 
stem cell in UCB is less than the other sources (ex: bone marrow), it can only be 
sufficient in pediatric patients. However, it does not reach the lower acceptable limit 
for an adult which is calculated according to body weight (~1,5-2x107/kg) (Gilmore 
et al., 2000; D’Alessandro et al., 2010). So that appropriate culture condition to 
increase the cell number for adult patients is needed.  
Currently, there are different MSC isolation techniques like use of magnetic beads, 
adherence to culture flasks, density gradient centrifugation (Godara et al., 2008), 
flow cytometry (Kang et al., 2006) etc. In this study, combination of density gradient 
centrifugation and adherence to plastic surface was used. RosettaSep® Human 
Mesenchymal Stem Cell Enrichment Cocktail was added to blood samples to cross-
link the undesired cells (especially red blood cells) before density gradient 
centrifugation. However, since this commercial product was designed for bone 
marrow, crosslinking of red blood cells couldn’t be succeeded efficiently for cord 
blood samples, so large amount of red blood cells were observed during cultivation. 
Therefore, its addition to UCB samples has no longer been a part of the isolation 
process. Just layering of blood samples to Ficoll-Paque (TM) Plus solutions was 
preferred before centrifugation step. 
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There is no specific surface marker for hMSCs; different sources used several 
markers for the characterization. MSCs are mostly characterized according to their 
self-renewal and multiple lineage differentiation capacity through these years (Kim 
et al., 2004). MSCs are positive for typical set of surface proteins; such as antigen 
CD9, CD10, CD13, CD55 (Pountos et al., 2007), CD54 (ICAM-1) (Kadivar et al., 
2006), CD29 (beta1-integrin), CD49b (alpha2-integrin), CD49d (alpha4-integrin), 
CD51 (alphaV-integrin), matrix receptors CD44 (hyaluronate receptor), CD58 (LFA-
3), CD105 (SH2-endoglin) (Lee et al., 2004), CD73(SH3), SH4 (Caplan, 2007), 
CD90 (Oswald et al., 2004), CD106 (vascular cell adhesion molecule [VCAM]-1), 
CD166 (activated leukocyte cell adhesion molecule) (Chamberlein et al., 2007), 
CD124 (Pittenger et al., 1999); but are negative for CD14 (Beiback et al., 2004), 
CD31 (Conget and Minguell, 1999; Alhadlaq and Mao, 2004), CD34 (an early 
hematopoietic marker) (Jazayeri et al., 2008; Fan et al., 2009) and also negative for 
CD45, CD133 (Lee et al., 2004), CD62 or von Willebrand factor (vWF) and 
expresses low levels of Flk-1 (Jiang et al., 2002). 
3.1 Phenotypic Analysis of MSCs by Flow Cytometry and Light Microscope 
Studies began with verification of the presence of MSCs. Combination of few 
markers such as CD44 (the hyaluronate receptor), CD90, CD105 (endoglin/Src 
homology domain-2) were used and results showed that the isolated cells were true 
MSCs (Figure 3.1 and 3.2). 
 
Figure 3. 1 : Negative control for CD90 and CD105 expression (left). Positive CD90 
and CD105 expression on MSCs (right). 
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Figure 3. 2 : Negative control for CD44 expression (left). Positive CD44 expression 
on MSCs (right).  
Kern et al. (2006) found that expression levels of these markers for bone marrow, 
umbilical cord and even for adipose tissue-derived MSCs may differ. 
UCB-MSCs showed some heterogeneity for couple of days. The adherent cells were 
observed on days 3 and 4. The spindle-shaped cells appeared at the bottom of culture 
flasks. Round cells were suspended in the medium but throughout the media 
refreshments, number of the suspended cells gradually decreased. MSCs adhered to 
the surface and produced a confluent monolayer with the predominant fibroblast-like 
shape of long and short spindles whereas the round cells observed were not 
considered as UCB-MSCs (Figure 3.3).  
Cells that were cultured in this study, reached confluency in nearly 14 days. 
In previous studies, UCB-MSCs were cultured in various types/combinations of 
medium solutions such as low-glucose DMEM (Ju et al.,2006) or α-Minimum 
Essential Medium (α-MEM) supplemented with l-glutamine, penicillin, streptomycin 
and FBS (Lee et al., 2005) or FCS (Wexler et al., 2003; Schmidt et al., 2006; Meyer 
et al., 2008). bFGF was also added to medium by Lee et al. (2004). Liu et al. (2007a) 
cultured UCB-derived MSCs with Iscove’s modified Dulbecco’s medium (IMDM) 
medium containing 20% FBS. In this study, commercially available medium 
MesenCult® was used for expansion, with no addition of penicillin or streptomycin, 
since all the cultivation was conducted in GMP conditions (Good Manufacturing 
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Practice). Culture medium was regularly replaced by fresh medium without 
disturbing or detaching the cells (Goltry et al., 2007). 
 
Figure 3. 3 : Fibroblastoid and adherent UCB-MSCs (200x, 22nd day). 
Wexler et al. (2003) also used cord blood as MSC source and they found that the 
samples produced a non-confluent adherent layer of heterogeneous cells, which did 
not proliferate beyond the initial inoculation, but as shown in figure 3.3, confluent 
and adherent cells grew at least for the next two subcultivation periods. 
Cells that grew in MesenCult® medium were harvested with a cell scraper for 
subcultivations. During this cell removal process, most of the cells were damaged via 
shear stress and lysed. We came to believe that this could be the main reason why 
those cells could not survive past the next 2 subcultivations. 
Therefore, to avoid this problem, another medium, called the Standard Medium, was 
adopted to recover cells from the flask surface by using trypsin-EDTA. With this 
modification, MSCs grew through 7 subcultures without losing viability. 
Morphological analysis of cells incubated in Standard Medium was shown in figure 
3.4.  
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Figure 3. 4 : (A) Day 7 (400x), (B) Day 14 (200x). Arrows show fibroblastoid 
MSCs. 
Flow cytometry analysis of cells from P(5) confirmed that Standard Medium also 
enhanced the growing of MSCs and increased the cell number. As shown on dot 
plots from figure 3.5 to figure 3.7, each cell is positioned on the X and Y scales, 
which are represented by dots, according to the fluorescence intensities detected. X-
axis plots green fluorescence intensity, where Y-axis shows red fluorescence 
intensity. Region E3 is for the negative cells for both markers, E4 and E1 represent 
green-only and red-only positive cells respectively, where E2 shows positive cells for 
both markers. So 41.8% of cells from P(5) expressed MSC antibody CD44, while 
46.5% of cells were positive for CD90 and also 72.9% of the cells did not expressed 
the HSCs markers CD34 and CD45.  
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Figure 3. 5 : 41.8% of the cells from P(5) showed positive expression for MSC 
marker CD44. 
 
Figure 3. 6 : 46.5% of the cells from P(5) showed positive expression for MSC 
marker CD90. 
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Figure 3. 7 : 72.9% of cells showed negative expression for both CD34 and CD45 
which is also characteristic of MSCs. 
However, when MSCs from P(6) and P(7) analyzed for MSC positive markers such 
as CD90, CD44 and CD73, results showed that there had been a decline in 
expression of surface antigens (Table 3.1).  
Table 3. 1 : Cell number (Cn). Percentages show the positive results. CD34/45 is 
negative marker for MSCs. 
Passages  CD90  CD44  CD73  CD34/45 
Passage 6  2.6%(Cn:5238)  3.2%(Cn:5434)  10.1%(Cn:5614)  0.2%(Cn:5220) 
Passage 7  3.5%(Cn:5217)  7.2%(Cn:5294)  15.4%(Cn:5392)  0.2%(Cn:5222) 
Comparison of these results with expression profile of cells from P (5) demonstrated 
possible changes in MSCs characteristics/expression profile (Figure 3.8). 
In addition to the expression differences, cells from P(6) reached confluency in 2 
weeks where cells from P(1) to P(5) had reached 70% confluency in 7 days. MSCs 
from P(7) were unable to reach 70% confluency on the flask surface in more than 20 
days. 
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Figure 3. 8 : Distribution of expression profiles for different passages. 
3.2 Endothelial Differentiation by VEGF 
Cellular therapy with hMSCs exhibit significant potential for use in regenerative 
medicine; especially in treatment of bone-, cartilage-, myocardium- and vascular 
tissue-based issues. Animal studies have already shown that injected hMSCs can 
differentiate into endothelial cells and SMCs that may function as vascular 
progenitors. Co-culturing of endothelial cells and hMSCs also yielded endothelial 
differentiation in DMEM medium and 2% FBS (Au et al., 2008). 
For in vitro endothelial differentiation, vascular growth factor was used in the current 
work. On the other hand, in previous in vitro studies to differentiate bone marrow 
MSCs into endothelia, insulin like growth factor-1 (IGF-1) with FBS addition to 
VEGF were also used by Jazayeri et al. (2008), and Oswald et al. (2004) used only 
FCS and VEGF. Furthermore, Liu et al. (2007b) chose an endothelial growth 
medium that included several growth factors in addition to VEGF. MSCs of UCB 
were chosen as a source for this type of differentiation, to observe whether this 
differentiation was going to be successful, a small-scale experiment was designed 
(Figure 3.9).  
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Figure 3. 9 : 6-well plate containing cells that received varied amounts of vascular 
growth factor. Control group, 40ng/ml, 45ng/ml, 50ng/ml, 55ng/ml 
and 60ng/ml respectively. 
For this experiment, freshly isolated mononuclear cells including MSCs from UCB 
were cultured in 6-well culture plates. First well was the control containing only the 
the EndoCult Medium® and the rest of the wells received various concentrations of 
growth factors for optimization of the endothelial differentiation. Concentrations of 
the applied VEGF were 40ng/ml, 45ng/ml, 50ng/ml, 55ng/ml and 60ng/ml. The 
medium containing appropriate ratio of growth factor was refreshed every 2-3 days. 
On the fifth day of culturing, light microscopy analyses exhibited the remarkable 
transition from bipolar fibroblast-like morphology to the cobblestone morphology 
(round shape which is a characteristic of endothelial cells) in each well (except the 
control group) (Figure 3.10). Control group mostly showed fibroblastoid shape, 
which proved that isolated cells remained as MSCs. 
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Figure 3. 10 : C:Control group without VEGF and different VEGF ratios on the 5th 
day of culturing (Mag.x10). 
On the other hand; thirteenth day observations showed that even the control group 
contained cells with cobblestone morphology (Figure 3.11). 
 
Figure 3. 11 : C:Control group without VEGF but with cobblestone morphology and 
different VEGF ratios on the 13th day of culturing (Mag.x10). 
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Application of 50ng/ml and 55ng/ml VEGF provided more efficient cellular 
differentiation with respect to the rest of samples, even in a short period of time (5 
days). Normally, for this differentiation MSCs were incubated in the presence of 
VEGF for 7 days, but to increase the number of cells, incubation time with growth 
factor was extended to 13 days. 
Besides from microscopic analysis, to investigate whether MSCs exhibit endothelial 
phenotype, flow cytometry analyses were conducted. For the identification of 
endothelial cells, FLT-1 (VEGF receptor 1), Flk-1/KDR (VEGF receptor 2), VE-
cadherin and VCAM-1 (vascular cell adhesion molecule-I) (Oswald et al., 2004), 
vWF (Opitz et al., 2004), CD31 (PECAM) (Sales et al., 2005), and CD34 (Watt and 
Contreras, 2005) were used as markers to characterize cells as true endothelial cells.  
After thirteen days, cells were harvested with PBS using cell scrapers to analyze 
positivity for some of these markers. CD144 (VE-Cadherin), CD106 (VCAM-1), 
CD309 (VEGFR-2/KDR) as well as CD44 that is also expressed on endothelial cells, 
were analysed. The results for each well, for different surface antigens were as 
follows (Table 3.2 and Figure 3.12): 
Table 3. 2 : Cell number (Cn). Percentages show the positive results. Highest values 
were highlighted. 
Samples CD144 CD44 CD106 CD309 
Control 1.4% (Cn:5287) 0.1%(Cn:5111) 0.2%(Cn:5136) 1.2%(Cn:5042) 
40ng 1.1%(Cn:5387) 0,6%(Cn:5431) 0.1%(Cn:5541) 0.9%(Cn:5478) 
45ng 1.1%(Cn:5490) 0.6%(Cn:5551) 0.1%(Cn:5498) 1.1%(Cn:5533) 
50ng 1.3%(Cn:5657) 1.5%(Cn:5730) 0.1%(Cn:5914) 1.0%(Cn:5933) 
55ng 1.5%(Cn:5966) 1.0%(Cn:6100) 0.1%(Cn:6265) 1.2%(Cn:6313) 
60ng 1.4%(Cn:6334) 0.9%(Cn:6322) 0.1%(Cn:6341) 0.9%(Cn:6326) 
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Figure 3. 12 : Distribution of expression profiles of different samples. 
As shown above, number of the differentiated cells were not as high as expected, 
thus, the percentages were not high. Besides, in control group, on 13th day 
cobblestone morphology was observed and flow cytometry results claimed that some 
markers were detected in higher quantities than the rest, regardless that the control 
well did not contain growth factor. This could be a result of the use of commercial 
EndoCult® Medium since it may already contain some growth factors inside.  
On the other hand, after flow cytometry analysis, similar to that reported in previous 
studies, 50ng/ml, and 55ng/ml VEGF application showed promising results (Oswald 
et al., 2004; Jazayeri et al., 2008). 
Secondly, MSCs from P(5) that was incubated inside the Standard Medium were 
chosen to differentiate into endothelial-like cells. Cells were seeded in 3 separate 
wells and treated with DMEM+20% FBS for a week followed by addition of VEGF. 
During this experiment, DMEM with FBS was used to avoid the undesired potential 
effects of EndoCult® on cells. Morphological changes of MSCs after introduction of 
VEGF were observed via microscopy (Figure 3.13).  
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Figure 3. 13 : Morphological changes in a week time with different ratios of 
VEGF(Mag.x10). 
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After 7 days of culturing with growth factor, cells were harvested to be analysed with 
flow cytometry to demonstrate the endothelial differentiation, by monitoring the 
expression levels of some endothelial markers such as CD144 (VE-Cadherin), 
CD309 (VEGFR-2/KDR), MSC-positive markers such as CD44, CD73, CD90, 
CD105 and MSC-negative markers such as  CD34, CD45, CD133. Results were 
listed below (Table 3.3): 
Table 3. 3 : Cn: Cell number. Percentages show the positive results. 
 
Cells treated with 50ng/ml expressed the highest results for endothelial markers and 
lowest results for CD90, CD105, CD34, CD45 which were all stem cell markers. 
Comparison of these results with the control, 50ng/ml and 55ng/ml results of a 
previous study (result of first experiment on Table 3.2 and Figure 3.12) is shown on 
Figure 3.14: 
 
Figure 3. 14 : Endothelial marker expression differences between 2 experiments. 
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Expression of endothelial cell markers exhibited some improvement in comparison 
to the first experiment, yet, they still did not reach high expression levels. This may 
be observed as a result of high number of subcultivation, since MSCs flow cytometry 
analysis of cells from P(5) and P(6) varied greatly as shown above on Figure 3.8.  
In order to compare the characteristics of the newly produced endothelial cells with 
native endothelial tissue, flow cytometry analysis of endothelial cells from native 
vessel were compared with those of our differentiated cells produced in the presence 
of 50 and 55 ng/ml of VEGF on Figure 3.15, with histogram plots. These plots are 
usually chosen to show a single parameter. X-axis is the intensity of the fluorescence, 
where Y-axis shows the cell number. Percentages give information about the percent 
of the cells that expressed markers positively. Results showed that the cells appeared 
to be real endothelial cells (Table 3.3).  
As seen in figure 3.15, MSC differentiation into endothelial cells did occur 
successfully even though the cell number was very low. On the other hand, some 
identifying markers of MSCs were higher, when they were compared to native vessel 
endothelial cell results, which meant there might be still MSCs that did not 
differentiate during cultivation with VEGF.  
MSCs from P(0) was also used for differentiation process. These cells could not 
reach 70% confluency for more than 30 days; however, incubation with human 
VEGF was attempted since the number of cells inside the culture increased during 
that period of time. 
From previous results; we concluded that no important diversities had occurred 
between the UCB-MSCs incubated with 50ng/ml and 55ng/ml VEGF, and also cells 
treated with 50ng/ml expressed the highest results for endothelial markers and lowest 
results for stem cell markers at the same time. Thus, for about 10 days, 50ng/ml 
human VEGF was added to medium in every 2 day, yet, microscopic observations 
revealed that there were still undifferentiated MSCs. Therefore, for the next 10 days 
we added human VEGF to the medium every day. Differentiation was analyzed via 
expression of endothelial markers (CD144, CD106 and CD 309) (Figure 3.16). 
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Figure 3. 15 : Flow cytometry analysis results of native endothelial cells and their 
comparison to differentiated MSCs. 
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Figure 3. 15 : (contd.) Flow cytometry analysis results of native endothelial cells and 
their comparison to differentiated MSCs. 
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Flow cytometry results of this third attempt was compared with native vessel 
endothelial cells from P(1) and P(2), which were treated with 1 hr and 24hr 
collagenase before cultivation, respectively (Figure 3.16): 
 
Figure 3. 16 : Flow cytometry comparison of 3 endothelial markers. X-axis: 
fluorescence intensity, Y-axis: cell number. 
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As shown on figure 3.16, the native vessel sample treated with collagenase for 24 hrs 
expressed higher endothelial markers rather than the ones treated for 1hr. Moreover, 
24hr-treated cells reached 70% confluency in a week (named as P(1)), but 1 hr-
treated cells reached confluency in 2 weeks. Besides, flow cytometry results of these 
two samples did not show high percentages for positivity for these three markers as 
expected because the existence of smooth muscle cells were also seen in culture 
flasks which increased the negativity for endothelial markers.   
On the other hand, UCB-MSCs, when cultured for longer periods with human 
VEGF, expressed the highest percentages for 3 markers. These results showed that 
during long cultivation, most of the UCB-MSCs differentiated into endothelial-like 
cells to express unique endothelial markers in the highest level (~90%). 
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4.  CONCLUSION 
Organ/tissue malfunctionings are the most devastating cases to handle in human 
health care. Engineered tissues may have an important place in clinical applications 
for tissue replacement or repair in the future. For cardiovascular diseases, UCB-
MSCs have significant potential for development of cell-based therapeutics to create 
small diameter living arteries suitable for transplantation applications.  
The present study reports the first step to develop small-diameter vascular grafts in 
vitro, by using UCB–derived MSCs. These cells are non-immunogenic (eliminating 
the risk of rejection), can be easily isolated and cryopreserved, and survive for many 
years, avoiding the ethical issues when compared to ESCs. Their in vivo potential to 
be used in gene and cell therapies, especially in treatment of mesenchymal 
injuries/disorders should be studied further. 
Results above confirmed that MSCs are present in the human cord blood and they 
show plasticity since differentiation into endothelial-like cells was observed.  
From the literature survey above, more research must be undertaken about stem cells 
and particularly, UCB-MSCs. For successful isolation of MSCs, there is a need for a 
specific marker. Also, an efficient way to expand the number of UCB-MSCs is 
needed, since low numbers are obtained from individual UCB samples; changing 
from person to person and time of the deliveries, affecting the reproducibility of the 
results. Moreover, the mechanism behind the differentiation and self-renewal 
properties of MSCs should be elucidated in order to work with them more efficiently. 
The current work showed that endothelial cells can be used to create a vessel model 
in future. To succeed in in vitro engineering of small-calibre autologous arteries, they 
should not only look like blood vessels but also should behave like them. Therefore, 
an ideal vascular graft should: 
• Be non-thrombogenic 
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• Serve as a synthetic ECM to support cell growth and tissue development to 
associate with surrounding connective tissue  
• Be biodegradable (matching with the rate of tissue development) 
• Have enough mechanical integrity to show tolerance to pulsatile nature, high 
pressure, and high flow rate of the bloodstream 
• Be elastic 
• Ease to handle and place 
• Be easily and economically manufactured in different diameters 
• Resistant to infections 
For the construction of vessels, which is identical to the native one, best scaffold 
materials with culturing procedures, and a real time monitoring way should be 
discovered to control the functioning status of the engineered vessel in vitro and in 
vivo.  
UCB-MSCs may be used as a natural system for repair to provide valuable 
autologous endothelial cells. Preparation of a vessel graft takes long time so, it 
cannot be used in emergencies but with the help of a bioreactor or a system, process 
of construction would be faster. Manipulating and activating resident stem cells to 
differentiate in vivo also remains as a challenge.  
Finally, foundation of new cord blood banks will give a chance to use 
autologous/allogenic cells of donors for future tissue engineering attempts to succeed 
in therapeutic goals. 
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